How are energy investors positioned?
In a recent filing with the Securities and Exchange Commission, Mikhail Eydelman, Senior Vice President, General Counsel, and Corporate Secretary of Vaxcyte, Inc. (NASDAQ:PCVX), disclosed the sale of company shares totaling $353,699. The transactions took place on March 5, 2025, and involved the sale of 5,000 shares of common stock at prices ranging from $70.388 to $72.37. According to InvestingPro data, Vaxcyte currently maintains a market capitalization of $9.28 billion and trades near $71.18 per share.
In addition to the sales, Eydelman also exercised stock options to acquire 5,000 shares at a price of $21.41 per share, amounting to a total value of $107,050. Following these transactions, Eydelman holds 41,620 shares of Vaxcyte stock directly. InvestingPro analysis shows the company maintains strong financial health with a current ratio of 12.75 and more cash than debt on its balance sheet.
The sales were executed under a Rule 10b5-1 trading plan, which was adopted on June 11, 2024. Such plans allow company insiders to set up a predetermined schedule for selling stocks, thereby helping to avoid potential accusations of insider trading. Discover more insights about Vaxcyte’s financial performance and access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Vaxcyte reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of -1.12, which met analysts’ expectations. However, the company did not provide a revenue forecast for the quarter. Despite maintaining a strong cash position of $3.13 billion, the stock experienced a decline following the earnings announcement. Vaxcyte’s ambitious product pipeline includes breakthrough vaccines like VAX31 and VAX24, which are crucial for its competitive position in the vaccine market. Mizuho (NYSE:MFG) Securities reiterated its Outperform rating for Vaxcyte, maintaining a $163 price target, suggesting confidence in the company’s long-term prospects despite recent stock fluctuations. The firm emphasized that the recent stock pressure was due to external political factors rather than company performance. Mizuho’s analysts remain optimistic about Vaxcyte’s future as macro political concerns are expected to diminish. Investors are closely monitoring Vaxcyte’s developments, particularly the upcoming release of infant primary series data for VAX24 and the initiation of a Phase 3 study for VAX31.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.